Jalra M 50 mg/ 500 mg
Available Dosages
| SKU | 2706 |
|---|---|
| Generic For | GALVUS |
| Manufacturer | USV Ltd., India |
| Active Ingredient | Vildagliptin + Metformin |
| Pack Size | Qty | Price Per Pill or Unit | Price | Cart | |
|---|---|---|---|---|---|
| 30 Tablet/s | US$ 1.00 | US$ 30.0017%US$ 36.00 | |||
|
|||||
| 60 Tablet/s | US$ 0.75 | US$ 45.0037%US$ 72.00 | |||
|
|||||
| 90 Tablet/s | US$ 0.72 | US$ 65.0040%US$ 108.00 | |||
|
|||||
Jalra M 50 500 mg (Vildagliptin + Metformin) – Affordable GALVUS Alternative
Jalra 50/500 mg is an oral anti-diabetic medicine containing two medicines, metformin and Vildagliptin, used to manage type 2 diabetes in adult patients whose diabetes can’t be controlled by diet and exercise alone or with other medications used to manage diabetes. It works best with a poor healthy diet and exercise program to control high blood sugar in people with Type 2 diabetes. Achieving high blood sugar levels helps prevent kidney damage, nerve problems, loss of limbs, and blindness.
Vildagliptin increases insulin release from the pancreas and decreases the hormones that increase blood glucose levels, thereby reducing fasting and post-meal sugar levels. Metformin reduces hepatic glucose production, reduces intestinal absorption of glucose, and improves insulin sensitivity by increasing glucose uptake and utilization. The combination is thus better effective in lowering blood sugar levels.
Do not take Jalra 50 500 mg if you are allergic to metformin, vildagliptin, or any of the other ingredients of the medicine. Avoid taking the medicine if you have uncontrolled diabetes, heart attack, a severe infection, liver problems, reduced kidney function, drink excessive alcohol, and are breastfeeding.
Avoid alcohol consumption during treatment with Jalra 50+500 mg as it may increase the risk of lactic acidosis.
Jalra M 50+500 mg side effects ?
Like all medicines, Jalra 50+500 mg can cause side effects, although not everybody experiences them.
You should stop taking this combination medicine and take immediate medical help if you develop any of the following:
- Lactic acidosis: Jalra may cause a rare but serious side effect called lactic acidosis.
- Angioedema: Symptoms include a swollen face, tongue, or throat, trouble swallowing, difficulty breathing, and sudden onset of hives or rash, which could cause a reaction called angioedema.
- Liver disease: Symptoms of the condition include nausea, loss of appetite, yellow skin and eyes, or dark-colored urine, which may indicate a liver disorder.
- Pancreatitis (Inflammation of the pancreas): Symptoms of the condition include severe and persistent pain in the stomach area, which might go through to your back, as well as nausea and vomiting.
Some common side effects of Jalra 50+500 mg include runny nose, sore throat, itchy rash, fever, excessive sweating, dizziness, headache, constipation, trembling that can’t be controlled, vomiting, diarrhea, flatulence, nausea, flatulence, heartburn, abdominal pain.
The amount of Jalra M 50+500 mg people take varies depending on their condition. Your healthcare provider will tell you the exact dose of this combination of medicines. Swallow the tablet whole with a glass full of water. One tablet in the morning and the other in the evening. Taking this combination medicine with food may reduce gastrointestinal symptoms associated with metformin. Your healthcare provider may recommend a lower dose if you have reduced kidney function. Also, if you are taking an anti-diabetic medicine called sulphonylurea, you may be advised to take a lower dose. You may be prescribed this medicine alone or with certain other medications that reduce the sugar level in the bloodstream.
Continue to follow any advice or diet restrictions your healthcare provider has given you. Specifically, if you are on a weight control diet, continue with this while taking metformin/Vildagliptin. Continue to take this medicine as long as it is prescribed to you so it can continue to control your blood sugar.
What is Vildagliptin + Metformin and what condition does it treat?
Vildagliptin + Metformin is a combination antidiabetic medication used to manage type 2 diabetes mellitus in adults. Jalra M 50 500 mg contains vildagliptin, a DPP-4 inhibitor, and metformin, a biguanide, working together to control high blood sugar levels. This dual-action diabetes tablet helps improve glycemic control when diet and exercise alone aren't sufficient. The combination therapy is prescribed for patients whose blood glucose isn't adequately managed with metformin or vildagliptin monotherapy. By combining two proven diabetes medicines into one convenient tablet, this treatment offers enhanced blood sugar management for better long-term health outcomes.
How does Vildagliptin + Metformin work in the body to lower blood sugar?
Jalra M 50 500 mg works through complementary mechanisms to reduce blood glucose levels. Vildagliptin increases insulin secretion when blood sugar is elevated and reduces glucagon production by inhibiting the DPP-4 enzyme. Metformin decreases glucose production in the liver, reduces intestinal glucose absorption, and improves insulin sensitivity in muscle tissue. This dual-action diabetes treatment addresses multiple metabolic pathways simultaneously. The synergistic effect of combining a DPP-4 inhibitor with a biguanide provides superior glycemic control compared to either component alone, helping patients achieve target HbA1c levels more effectively while minimizing blood sugar fluctuations throughout the day.
How long does Jalra M 50 500 mg take to work after starting treatment?
Jalra M 50 500 mg begins lowering blood sugar within hours of the first dose, though noticeable improvements in glucose readings typically appear within a few days. Optimal glycemic control with this vildagliptin metformin combination usually develops over two to four weeks as the medication reaches steady-state levels. Your HbA1c test, which measures average blood sugar over three months, will show the full therapeutic benefit after approximately 12 weeks of consistent use. Individual response times vary based on baseline glucose levels, diet adherence, and other factors. Regular blood sugar monitoring helps track your progress on this antidiabetic medication during the initial treatment period.
When and how should I take Jalra M 50 500 mg for best results?
Take Jalra M 50 500 mg exactly as prescribed, typically twice daily with meals to reduce gastrointestinal side effects associated with metformin. Swallow the tablet whole with water—don't crush or chew it. Taking this diabetes medication with food also optimizes absorption and helps maintain steady blood glucose control throughout the day. Most prescribers recommend morning and evening doses approximately 12 hours apart. Consistency matters: taking your vildagliptin metformin combination at the same times daily maximizes effectiveness. If you miss a dose, take it as soon as remembered unless it's nearly time for your next scheduled dose. Never double up to compensate for forgotten tablets.
Is Jalra M 50 500 mg safe for long-term use in diabetes management?
Jalra M 50 500 mg is designed for long-term use in managing type 2 diabetes mellitus and has demonstrated a favorable safety profile in extended clinical studies. Many patients take this vildagliptin metformin combination for years as part of their ongoing diabetes treatment plan. Regular monitoring through periodic blood tests helps ensure the medication continues working safely and effectively. Your healthcare provider will check kidney function, liver enzymes, and vitamin B12 levels during long-term therapy, as metformin can occasionally affect these parameters. The DPP-4 inhibitor component is generally well-tolerated with chronic use. Most patients experience sustained glycemic control with this antidiabetic medication over extended treatment periods.
Can I take Jalra M 50 500 mg with other medicines or supplements?
Jalra M 50 500 mg may interact with certain medications, making medical supervision essential when combining treatments. This diabetes tablet can interact with other glucose-lowering drugs, increasing hypoglycemia risk. Medications affecting kidney function may alter metformin clearance, while some blood pressure medicines and diuretics can impact blood sugar control. Contrast dyes used in imaging procedures require temporary discontinuation of this antidiabetic medication. Alcohol consumption should be limited as it can increase lactic acidosis risk with metformin. Always inform healthcare providers about all medications, supplements, and herbal products you're taking before starting vildagliptin metformin combination therapy to avoid potentially dangerous drug interactions.
How does Jalra M 50 500 mg compare to other diabetes combination tablets?
Jalra M 50 500 mg offers distinct advantages among antidiabetic combination therapies. Unlike sulfonylurea-metformin combinations that may cause weight gain and hypoglycemia, this vildagliptin metformin combination provides glucose-dependent insulin secretion, reducing low blood sugar risk. Compared to SGLT2 inhibitor combinations, this DPP-4 inhibitor plus biguanide pairing doesn't increase urinary tract infection risk. The medication offers effective HbA1c reduction comparable to other combination diabetes medicines while maintaining weight neutrality. Its twice-daily dosing provides consistent 24-hour glycemic control. The tolerability profile of Jalra M is generally favorable, with fewer gastrointestinal effects than some alternative combination tablets, making it suitable for diverse patient populations requiring dual diabetes therapy.
Is generic Vildagliptin + Metformin as effective as branded Jalra M 50 500 mg?
Generic vildagliptin + metformin combinations are therapeutically equivalent to branded Jalra M 50 500 mg, containing identical active ingredients at the same strengths. Regulatory authorities require generic diabetes medications to demonstrate bioequivalence, meaning they deliver the same amount of drug to your bloodstream as branded versions. Both formulations provide the same blood sugar lowering effects, safety profile, and clinical outcomes. The primary difference lies in cost—generic antidiabetic tablets typically offer significant savings while maintaining quality and efficacy. Whether choosing branded or generic versions of this DPP-4 inhibitor metformin combination, patients receive effective type 2 diabetes management. Many healthcare systems prefer generics due to comparable therapeutic benefit at reduced expense.
Why do patients choose PremiumRxDrugs for their Jalra M 50 500 mg prescription?
Patients select PremiumRxDrugs for Jalra M 50 500 mg because of the pharmacy's proven reliability, competitive pricing, and commitment to authentic medications. As a licensed online pharmacy, we have been serving diabetes patients for over ten years, building trust through consistent delivery of manufacturer-sourced vildagliptin metformin tablets. Customers appreciate the transparent pricing on both branded and generic diabetes medicines, making long-term treatment more affordable. The convenient reorder system, discreet packaging, and worldwide shipping including free delivery options add practical value. Patients across the USA, UK, Australia, and Canada rely on PremiumRxDrugs for accessible, genuine antidiabetic medications without compromising quality. The combination of affordability, authenticity, and customer service makes PremiumRxDrugs a preferred source for ongoing diabetes management needs.
What are the common side effects of Vildagliptin + Metformin?
Common side effects of Vildagliptin + Metformin include gastrointestinal symptoms like nausea, diarrhea, stomach upset, and metallic taste, primarily from the metformin component. These digestive effects often diminish as your body adjusts to the diabetes medication. Headache and dizziness occur occasionally with this antidiabetic combination. Some patients experience hypoglycemia if taking other glucose-lowering medicines concurrently. Upper respiratory tract infections and nasopharyngitis have been reported with the DPP-4 inhibitor component. Rarely, lactic acidosis—a serious but uncommon metformin complication—can occur, particularly in patients with kidney problems. Most people tolerate this biguanide and DPP-4 inhibitor combination well, with side effects being mild and manageable through proper dosing and administration with meals.
Who should avoid taking Vildagliptin + Metformin?
Vildagliptin + Metformin is contraindicated for individuals with severe kidney impairment, as metformin elimination depends on renal function. People with acute or chronic metabolic acidosis, including diabetic ketoacidosis, should not use this antidiabetic combination. Those with severe liver disease, heart failure requiring medication, or conditions causing tissue hypoxia should avoid this diabetes treatment. Patients with known hypersensitivity to DPP-4 inhibitors or biguanides cannot take this medication. It's not suitable for type 1 diabetes or diabetic ketoacidosis management. Pregnant or breastfeeding women typically shouldn't use this combination therapy. Anyone scheduled for surgery or contrast imaging procedures requires temporary discontinuation. Always disclose your complete medical history before starting any glucose-lowering medication.
Login
Sign Up
Login
Sign Up